PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
JACC Basic Transl Sci. Author manuscript; available in PMC 2017 September 22.
Published in final edited form as:
PMCID: PMC5609457
NIHMSID: NIHMS881711

Metabolic Origins of Heart Failure

Summary

For more than half a century, metabolic perturbations have been explored in the failing myocardium, highlighting a reversion to a more fetal-like metabolic profile (characterized by depressed fatty acid oxidation and concomitant increased reliance on glucose utilization). More recently, alterations in ketone body and amino acid/protein metabolism have been described during heart failure, as well as mitochondrial dysfunction and perturbed metabolic signaling (e.g., acetylation, O-GlcNAcylation). Although numerous mechanisms are likely involved, the current review provides recent advances regarding the metabolic origins of heart failure, and their potential contribution toward contractile dysfunction of the heart.

Keywords: amino acids, fatty acids, glucose, heart failure, ketone bodies

Overview

In order to meet the exceptionally high metabolic demands of continuous contractility, the heart catabolizes a vast array of substrates. Indeed, the heart has been termed a ‘metabolic omnivore’, capable of consuming fatty acids, glucose, ketone bodies, and amino acids, for the replenishment of ATP. Central to achievement of this goal is metabolic flexibility, wherein the heart shifts reliance from one substrate to another, in response to acute perturbations in workload and/or substrate availability (including feeding-fasting and sleep-wake cycle, which occur on a daily basis). The importance of metabolic flexibility is underscored by appreciation that various substrates are more than just a fuel for the heart, serving also as building blocks for numerous cellular components (e.g., membranes, proteins), cofactors, and signaling molecules. During various disease states, particularly heart failure (HF), cardiac metabolism is perturbed in a chronic manner, resulting in metabolic inflexibility. Thus, HF is characterized by relatively permanent and predictable shifts in metabolism, associated with impaired signaling (e.g., Ca2+, ROS), energy insufficiency, and contractile dysfunction. The purpose of this review is to highlight recent insights regarding the metabolic basis of heart failure; for the contribution of perturbed Ca2+ homeostasis and ROS signaling, the reader is directed to the following reviews (1,2).

Contributions of Individual Substrates

Fatty Acid Metabolism

Fatty acid oxidation (FAO) represents a significant fuel source for the myocardium, providing an estimated 50%-70% of the ATP consumed during contraction (reviewed in (3)). In comparison to carbohydrate utilization, rates of cardiac FAO are relatively unaffected by acute changes in workload/energetic demand (4,5). Cardiac FAO typically exhibits greater flexibility following changes in substrate availability (6). Such observations could be generalized as an indication of FAO to maintain baseline energetic needs of the heart, while at the same time matching rates of fatty acid uptake with oxidation. If true, then deficits in cardiac FAO could potentially precipitate contractile dysfunction through energetic impairment and/or diverting of excess fatty acids into signaling and/or ‘lipotoxic’ pathways. The purpose of this subsection is to review evidence supporting these concepts.

One of the most consistent metabolic perturbations during HF is decreased fatty acid utilization, being observed in both animal-based and human studies (7-11). In doing so, the failing heart reverts to a fetal-like metabolic program, reflected by a repression of various genes encoding for core FAO pathway proteins (e.g., medium chain acyl-CoA dehydrogenase, beta-hydroxyacyl-CoA dehydrogenase) and their upstream regulators (e.g. PPARα, RXRα, PGC-1α) (12,13). It has been proposed that acutely this metabolic perturbation serves as an adaptation, by promoting increased reliance on more energetically efficient fuels (in terms of ATP per oxygen molecule consumed), which may be particularly important in the setting of ischemic heart disease (14). Consistent with this concept, attenuation of FAO is observed prior to the onset of contractile dysfunction (induced, for example, by pressure overload) (15). However, this metabolic reprogramming causes chronic dyssynchrony between energetic demand (which is increased), substrate availability (circulating fatty acids are typically increased), and utilization (i.e., FAO is decreased) during HF. In other words, a decrease in FAO rates could reduce ATP availability for contraction (if below the capacity of alternative compensating pathways) concomitant with increased diverting of fatty acid species into signaling/lipotoxic pathways, culminating in contractility impairment. Evidence in support of this concept includes reports of modest perturbations in markers of energetic status in the failing myocardium, as well as accumulation of lipotoxic markers (16-18). The latter, when elevated, can contribute to cell death and cardiac remodeling.

Energetic Deficiency versus Lipotoxicity

Both genetic and pharmacologic approaches have been utilized to address causal relationships between FAO impairment and HF. Genetic studies revealed that inborne errors of FAO, such as inherited deficiencies in acyl-CoA dehydrogenases, can be associated with cardiomyopathy in humans; similar pathologies are often recapitulated through targeted genetic manipulation in mouse models (reviewed in (19)). One example includes very long chain acyl-CoA dehydrogenase (VLCAD); germline deletion results in energetic impairment and a cardiomyopathic phenotype (20). Importantly, cardiac-restricted VLCAD deletion also results in contractile dysfunction, illustrating the importance of normal cardiac FA metabolism (21). Similarly, genetic deletion of lipoprotein lipase (LPL; liberates fatty acids from circulating lipoproteins), long chain acyl-CoA synthetase 1 (ACSL1; activates long chain FAs for metabolism), and adipose triglyceride lipase (ATGL; liberates fatty acids from intracellular triglyceride stores) result in concomitant decreases in cardiac FAO and contractile function (22-24). It is noteworthy, however, that genetic mutations resulting in decreased cardiac FAO do not always result in contractile dysfunction. For example, knockout of CD36 (fatty acid transporter) or PPARα/PGC-1α (transcription factors promoting FAO/mitochondrial metabolism) results in decreased FAO without effects on basal contractility (25-27). Possible explanations for the latter discrepancies include: 1) FAO is only modestly impaired; 2) sufficient compensation from alternative substrate utilization occurs; 3) diverting of fatty acids species into lipotoxic pathways is limited; and/or 4) a secondary stress is required to elicit dysfunction (e.g., pressure overload, high fat diet, etc).

If acquired deficiencies in cardiac FAO were to contribute significantly towards contractile dysfunction of the failing myocardium, then normalization of the fatty acid oxidation deficit would be predicted to improve contractility. Both genetic and dietary strategies have been employed to address this concept. An important example includes the study by Kolwicz et al, wherein selective deletion of acetyl-CoA carboxylase 2, an enzyme that generates malonyl-CoA (a potent inhibitor of β-oxidation), prevents pressure overload-induced depression of fatty acid oxidation, and concomitantly maintains contractile function (28). Interestingly, feeding rodents calorically-dense high fat diets has been shown to preserve/improve contractility in distinct models of heart failure (including pressure overload, myocardial infarction, and hypertension), although not all studies report this benefit (perhaps due to differences in dietary composition, duration of feeding, etc) (29-33). Observations such as these raise the question whether cardiac FAO impairment primarily leads to energetic deficiency, as opposed to lipotoxicity/signaling imbalance. However, strategies designed to cause a mismatch between FA uptake and FAO (e.g., overexpression of FATP1 or ACSL1) invariably result in cardiomyopathy, associated with markers of lipotoxicity (34,35). In addition, the failing heart is considered to be in a pro-lipotoxic environment (36). Furthermore, haploinsufficiency of mCPT1 increases susceptibility to pressure overload-induced cardiac dysfunction through lipotoxic pathways (37). Similarly, germline VLCAD deletion increases cardiac lipotoxicity during high fat feeding (38). Collectively, these studies suggest that impaired cardiac FAO could lead to cardiac dysfunction not only through energetic deficiency, but also through lipotoxicity.

Mediators of Depressed FAO during HF

Various mechanisms have been proposed as mediators of cardiac FAO impairment during HF. These include transcriptionally-based mechanisms, post-translational modifications (PTMs), mitochondrial dysfunction, cofactor availability, and substrate competition. With regards to transcriptionally-based mechanisms, particular attention has been given to multiple PPAR isoforms (particularly PPARα); upon complex formation with RXRα, FAs (ligand), and coactivators (e.g., PGC-lα), PPARα induces a number of genes encoding for known FA transporters and core (β-oxidation enzymes (reviewed in (13)). Importantly, during HF, cardiac levels of PPARα, RXRα, and PGC-lα have been shown to decrease to varying degrees, associated with decreased expression of target genes (8,12). Furthermore, PPARα activity may be repressed further through PTMs (39). The enzymes involved in FA metabolism also undergo PTMs during HF, such as acetylation; this PTM potentially promotes FAO in the heart both directly (i.e., acetylation and activation of β-oxidation enzymes) and/or indirectly (i.e., acetylation and inhibition of pyruvate dehydrogenase, and therefore impairment of glucose oxidation) (40,41). It is noteworthy that cardiac FAO capacity is extremely high, such that enzymes involved in β-oxidation must be inhibited markedly in order to impact FAO flux. This is exemplified by VLCAD and CPTlb heterozygous knockout mouse hearts, which exhibit no baseline phenotype despite a 50% loss in enzymatic activity (21,37); homozygous cardiomyocyte-specific knockout of VLCAD also has no significant effects on cardiac FAO rates, likely due to compensation by other acyl-CoA dehydrogenase isoforms (e.g., LCAD) (21). In contrast, cardiac FAO is affected by cofactor availability (e.g., carnitine, CoA) and/or mitochondrial function, which are decreased in the failing myocardium (42-44); decreased carnitine would attenuate mitochondrial fatty acid uptake, decreased CoA would attenuate β-oxidation, while limited mitochondrial electron transfer would attenuate dehydrogenases in the β-oxidation spiral. Furthermore, increased reliance on alternative substrates (e.g., glucose and ketone bodies, as discussed below) during HF would attenuate FAO through established allosteric and cofactor limitation mechanisms. In the failing myocardium, all the above referenced mechanisms likely contribute towards attenuated FAO.

Glucose Metabolism

Cardiac glucose utilization (i.e., glycolysis and glucose oxidation; GLOX), is important for the developing (fetal) heart, during which time glucose delivery is high, and oxygen availability is relatively low (45). Soon after birth, glucose utilization decreases concomitant with increased dietary FA and oxygen delivery. However, the healthy adult heart has the capacity to increase reliance on glucose utilization in response to both physiologic (e.g., exercise) and pathologic (e.g., ischemia) stresses. During HF, metabolic flexibility is lost, which may be due in part to cardiac insulin resistance (IR); complex alterations in insulin signaling within cardiomyocytes during HF have been reviewed recently (46). It has been suggested that under some circumstances (e.g., hemodynamic stress) that IR may actually protect the heart, by reducing fuel toxicity (47). However, as HF progresses, an uncoupling between glycolysis and GLOX ensues, potentially contributing towards cellular dysfunction (48). Interestingly, circulating glucose levels tend to be elevated during both acute and chronic HF. For example, elevated serum glucose levels at the time of hospital admission for acute HF syndromes, independent of diabetes status, are associated with higher mortality (49,50). Chronically, HF is also associated with peripheral IR. Whether these perturbations in cardiac and/or whole body glucose homeostasis contribute to the pathogenesis of HF is still under debate (51). The purpose of this subsection (summarized in Figure 1) is to review current knowledge regarding the utilization of glucose during heart failure; we will focus primarily on this independent of diabetes status, as the latter has been reviewed extensively elsewhere (52-54).

Figure 1
Glucose Contributions to Myocardial Dysfunction during Heart Failure

Whether perturbations in cardiac glucose utilization are adaptive or maladaptive during HF appears to be dependent on the underlying stress (i.e., ischemic versus non-ischemic), as well as duration (i.e., acute versus chronic). In the context of hypertension induced dilated cardiomyopathy, glucose utilization is increased, with a predominate augmentation of glucose uptake and glycolysis, and a concomitant uncoupling of glycolytic flux from GLOX (48,55). There is mounting evidence that the remodeling of glucose metabolism is one of the initial changes driving the heart to hypertrophy and could act as an early marker of disease progression (56). Acutely enhancing glucose metabolism in the setting of ischemic injury and ventricular fibrillation may be protective (57,58).

Glucose Transport During HF

Regulation of glucose uptake into the cardiomyocyte is regulated by members of the solute carrier family 2A (SLC2A) that encode the GLUT proteins (55,59). Of the twelve SLC2A genes expressed in human and rodent cardiac tissue, three are predominantly expressed in the myocardium: GLUT1, GLUT4, and GLUT8 (60). Of these GLUT1 and GLUT4 have received extensive attention, in part due to observations that both are decreased in failing human hearts (61). Such observations are consistent with repressed insulin-mediated glucose uptake (primarily through GLUT4) during HF, potentially secondary to chronic activation of GRK2 and IR (62). However, during HF, basal rates of glucose uptake and glycolysis are elevated (and even exceed rates of glucose oxidation) (63). One possible explanation for this apparent disconnect is increased GLUT translocation/activity, in an insulin-independent manner. A number of cardiomyocyte-specific gain- and loss-of-function models have been employed in an attempt to address this question, as well as the importance of glucose utilization during HF.

A number of studies have interrogated the importance of various GLUT isoforms in the maintenance of cardiac function. Lifelong GLUT1 overexpression protects against pressure overload-induced contractile dysfunction (64), while acute GLUT1 augmentation partially rescues disease progression (65), suggesting that enhanced glucose uptake is protective in this setting. However, cardiomyocyte-specific ablation of GLUT1 did not exacerbate pressure-overload induced dysfunction (perhaps due to sufficient glucose uptake by other GLUT isoforms) (66). Conversely, cardiomyocyte specific GLUT4 ablation decreased functional recovery in response to ischemic injury (67). Although loss of GLUT8 has been explored in the context of diet-induced obesity (68), a direct role during HF remains to be explored. Studies of these transporters, as well as those of the other cardiac enriched GLUTs (GLUT3, GLUT10, and GLUT12), will continue to provide crucial insight into the contribution of glucose uptake and metabolism during the progression of HF.

An emerging area has focused on non-GLUT mediated glucose transport via the sodium-glucose cotransporters (SGLT), especially given that empagliflozin (an SGLT2 inhibitor) decreased HF incidence in diabetic patients (69). The mechanism of this protection is likely multifaceted, including both glucose and sodium lowering, as well as influences on glomerular filtration and the cardiorenal axis (70). Interestingly, SGLT1 is induced in the heart during both diabetic and ischemic cardiomyopathy (71), and phlorizin (another SGLT inhibitor) decreased cardiac glucose uptake and directly affects tolerance of the heart to ischemia (72). Future studies will undoubtedly reveal important insights regarding the effects of SGLT inhibitors on cardiac metabolism and protection.

Polyol pathway

Augmented glucose uptake and glycolytic flux, particularly when in excess of GLOX, enhances diverting of glucose moieties into signaling pathways. This includes the polyol pathway. Although primarily implicated in diabetic complications, overexpression of aldose reductase (AR), the first step in this pathway, results in an age-related decline in heart function and exacerbated ischemic injury (73). Further studies are warranted in order to elucidate fully the importance of the polyol pathway in the pathogenesis of HF.

Pentose phosphate pathway (PPP)

The PPP is important for NADPH and ribose-5-phosphate generation. In a canine model of congestive HF, post-prandial glycemic levels were sufficient to increase PPP flux. When this was prevented, cardiac GLOX and stroke work were normalized (74). Furthermore, in a genetic mouse model of dilated cardiomyopathy that progresses to HF, non-oxidative glucose pathways such as the PPP and glycogen synthesis were increased (75). The PPP affects ROS balance, not only through NADPH, but via regulation by pyridine nucleotides (76). Interestingly, glucose-6-phosphate dehydrogenase (G6PD; first enzyme of the PPP) deficiency is associated with cardiac disease progression; however, mice with G6PD deletion have shown both protective and deleterious effects on cardiac function (77), suggesting the need for further study.

Hexosamine biosynthesis pathway (HBP)

The HBP requires input from glucose, amino acids, fatty acids, and nucleotides, resulting in the end product, UDP-GlcNAc. This molecule in turn is used to regulate nearly all aspects of cell physiology via the PTM of serine and threonine residues by the addition of an O-linked N-acetylglucosamine (O-GlcNAc) (78).This O-GlcNAc modification is elevated in both hypertrophy and HF (79), and has both adaptive and maladaptive contributions to cardiac function (80,81). Specifically, increased O-GlcNAc is protective following acute ischemic injury, while during HF, elevated O-GlcNAc may contribute to contractile and mitochondrial dysfunction. O-GlcNAc likely impacts a number of cardiac processes, including transcription, epigenetics, metabolism, and Ca2+ handling. In the latter case, O-GlcNAc can regulate SERC2A, CaMKII, and STIM1 (82-85), either increasing or decreasing calcium sensitivity depending on the duration and disease state (e.g., ischemic or non-ischemic).

Ketone Body Metabolism

Compared with fatty acid and glucose metabolism, current knowledge of the role of altered ketone body metabolism during HF is relatively limited. However, a growing body of evidence from pharmacological (86,87), dietary (87-90), and genetic (91) manipulation studies suggest that perturbations of ketone body utilization can play a role in cardiac health and disease. The heart readily utilizes ketone bodies, such that their oxidation is typically increased in proportion to their delivery (92). Acetoacetate (AcAc) and β-hydroxybutyrate (βOHB) are the primary ketone bodies that can be metabolized, which are synthesized by the liver during periods of elevated fatty acid availability, including fasting, prolonged exercise, ketogenic diets, uncontrolled type 1 diabetes, and HF (93). In the latter case, multiple studies have consistently shown that HF patients with no previous history of diabetes present with elevated levels of systemic ketone bodies (94,95). During heart failure, elevated norepinephrine levels secondary to increased sympathetic outflow likely promotes ketogenesis by increasing fatty acid supply via lipolysis in adipose tissue (96). The strength of these associations is such that exhaled acetone (indication of ketoacidosis) is a predictive biomarker for severity of heart failure (97-99). It is noteworthy, however, that a recent study reported reduced circulating ketone body levels in HF patients with reduced ejection fraction (EF) relative to HF patients with preserved ejection fraction and non-HF controls (100). Severity of HF and other co-morbidities associated with the patients recruited in these studies could potentially account for these discrepancies.

Whether altered myocardial ketone body metabolism contributes to the pathogenesis of HF was recently investigated in rodents and humans (101,102). These studies reported increased expression of ketone body metabolism enzymes (D-β-hydroxybutyrate dehydrogenase (BDH1) and succinyl-CoA:3-oxoacid CoA transferase (SCOT), reduced intermediary metabolites of ketone body catabolism, as well as increased ketone body oxidation (stable isotope measurements) in the failing heart. An important question relates to whether increased ketone body utilization during HF is adaptive or maladaptive. In support of an adaptive role, cardiomyocyte-specific deletion of SCOT led to adverse cardiac remodeling following pressure overload (91). However, these studies do not address whether normalization of ketone body utilization, particularly in the setting of heart failure, is beneficial or detrimental (as opposed to ablation during compensated hypertrophy). Interestingly, elevated ketone body availability would be anticipated to repress both FAO and GLOX in the heart through substrate competition, thus resulting in a metabolic signature reminiscent of advanced HF. Furthermore, ketone bodies serve as signaling molecules, acting through both extracellular receptors (e.g., GPR41) and intracellular inhibitors of histone deacetylases (HDACs) (86,103), which in turn could influence cardiac processes (Figure 2). The mechanisms by which ketone body utilization enzymes are induced during HF also remain unanswered. Future studies interrogating these questions are warranted, which will aid in understanding the role ketone body metabolism in the pathogenesis of HF.

Figure 2
Myocardial Ketone Body Metabolism in the Failing Heart

Amino Acid Metabolism

When compared to fatty acids and glucose, amino acids quantitatively contribute to a lesser degree towards ATP generation in the heart. However, amino acids play essential roles in myocardial function that extend beyond energetics, such as synthesis of protein, metabolic/signaling intermediates, and cofactors. In the latter case, notable amino acid derivatives include L-carnitine (from lysine and methionine), CoQ10 (from tyrosine and mevalonate), and Taurine (from methionine or cysteine), which play important roles in cardiac processes (e.g., metabolism, redox biology, and calcium homeostasis). Furthermore, it has been estimated that the mammalian heart renews all cellular components within a 30-day period (50), illustrating a significant demand on amino acid availability for protein and cofactor synthesis. Moreover, protein turnover is accelerated in the heart during periods of remodeling, such as hypertrophic growth. Significant efforts have been made to increase our understanding of amino acid metabolism perturbations during HF and have yielded novel insights. This sub-section (summarized in Figure 3) highlights the contribution that amino acid metabolism perturbations potentially play in the etiology of HF.

Figure 3
Perturbations in Amino Acid Metabolism During Heart Failure

Amino Acids during HF

Both amino acid availability and utilization are influenced by HF. For example, profiling plasma amino acids (and their derivatives) from HF patients using HPLC revealed that the circulating levels of almost half of the species assessed (17 of 41) were altered in HF, the vast majority of which were increased (15 of 17) (104). Furthermore, a subset of these amino acids, including glutamate and monoethanolamine (a serine derivative), negatively correlated with EF in HF patients (with trends for phenylalanine and tyrosine as well), suggesting higher circulating amino acids were indicative of worsening cardiac function. This is likely due to accelerated protein breakdown in skeletal muscle, which serves as an amino acid reservoir during HF (105). Despite increased demand for amino acids in the heart, there is evidence of AA accumulation in the failing myocardium; metabolomic analysis of failing mouse myocardium showed accumulation of amino acids, consistent with the notion that AA catabolism was compromised (106). Transcriptomic analysis in mice shows that genes associated with amino acid catabolism are down regulated during compensated hypertrophy and overt failure (106).

Considerable interest has been placed on branched-chain amino acid (BCAA; leucine, isoleucine, valine) metabolism during HF. Branched chain α keto acids (BCKA; product after initial step of BCAA catabolism) are elevated within the myocardium in human HF patients (107). Furthermore, subunits of the branched chain alpha-keto acid dehydrogenase (BCKD) complex, which is responsible for subsequent catabolism of BCKA's, are transcriptionally repressed. These findings have been replicated in mice during TAC-induced HF, where, pharmacologic activation of BCKD normalized BCAA catabolism, prevented BCKA accumulation and protected against cardiac dysfunction (107). These findings suggest that an imbalance between BCAA availability and utilization during HF may contribute towards contractile dysfunction, and that normalization of this balance may be a novel, efficacious therapeutic strategy.

Consistent with impairment of appropriate amino acid utilization/metabolism by the failing myocardium, various cofactors are often found to be depleted. This includes taurine. The importance of taurine in the heart is supported by studies using taurine deficient mice (induced by genetic ablation of the taurine transporter; TauT) and rats (TauT inhibition with β-alanine), resulting in cardiomyopathy (108). Taurine deficiency is characterized by reduced glucose and fatty acid oxidation in isolated perfused rat hearts (109), reduced mitochondrial complex I and III activity, and increased ROS production in cardiomyocytes (110). Taurine deficiency is also associated with aberrant Ca2+ homeostasis/signaling, involving alterations in phospholamban and SERCA2 (111). Taurine supplementation has been shown to be efficacious during HF, eliciting improvements in LV function (112) and exercise capacity (113).

Various studies suggest that amino acid supplementation increases functional capacity and quality of life in patients with chronic stable HF (reviewed here (114)). For example, mixed amino acid supplementation increased functional exercise capacity (VO2 peak, exercise time during exercise test, 6-minute walk test) in humans with chronic HF (115,116). Similarly, BCAA supplementation preserved cardiac function during high salt-induced heart failure in Dahl salt-sensitive rats (a physiological model of hypertension leading to HF) (117). These somewhat counterintuitive observations (i.e., beneficial effects of amino acid supplementation during HF, when amino acid availability appears to exceed capacity of the myocardium to metabolize them) may be explained by extra-cardiac effects. For instance, BCAA supplementation represses skeletal muscle cachexia (i.e., muscle wasting), and previous studies suggest that the degree of cachexia is a strong independent risk factor for mortality during HF, and significantly reduces survival (118).

Amino Acids Regulate Signaling during HF

Various amino acids (and their derivatives) function as signaling molecules. This is particularly true for BCAAs, which activate the mammalian target of rapamycin (mTOR), a modulator of various anabolic (i.e., protein synthesis) and catabolic (i.e., autophagy, see next sub-section) pathways. Aberrant mTOR signaling has been implicated in the progression of HF (119,120). In mice, mTOR is activated by pressure overload, and pharmacologic inhibition (with rapamycin) improves contractile function of the decompensated myocardium (121). However, ablation of mTOR complex 1 signaling (via genetic deletion of Raptor) prevents compensated hypertrophy following pressure overload (122), resulting in a rapid transition to HF and increased mortality. These findings suggest mTOR activation may be adaptive during the initial compensated phase, but maladaptive during overt failure. It is noteworthy that BCAAs also appear to affect cellular processes in an mTOR-independent manner, potentially through the eukaryotic initiation factor 2 alpha (eIF2α) kinase general control nonderepressible 2 (GCN2). GCN2 is activated by non-charged tRNA during AA starvation (particularly BCAA depletion), which leads to eIF2α phosphorylation and repression of translation. Interestingly, when exposed to pressure overload, GCN2 null mice are protected against contractile dysfunction (123), raising the possibility that BCAA supplementation may afford some protection during HF through GCN2 inhibition.

Autophagy and the Ubiquitin Proteasome System during HF

Turnover of cellular components (such as proteins) is essential for maintenance of function, especially in terminally differentiated cells with limited capacity for renewal, such as cardiomyocytes. Several cellular processes, including autophagy and the ubiquitin proteasome system (UPS), are critical for the turnover/degradation of proteins and organelles, and therefore myocardial quality control. While target-specific forms of autophagy exist, including mitophagy (mitochondria), glycophagy (glycogen) and lipophagy (lipids), this sub-section will focus on macroautophagy (hereafter referred to as autophagy).

Observational evidence (e.g., electron microscopy) in humans with ischemic and dilated cardiomyopathy, as well as congestive heart failure, suggests that autophagy might be induced in the stressed myocardium (124,125). Paired sampling of cardiac tissue during left ventricular assist device (LVAD) implantation/explantation indicates autophagy markers are increased during HF, and are reduced following mechanical unloading (126). However, difficulties with measuring autophagic flux in static samples can hinder interpretation of observational results in clinical human studies, necessitating the use of animal models. Experimental evidence in mice subjected to pressure overload indicated transient activation of autophagy, which is elevated within hours of TAC in mice, returning to sub-basal levels within days (127,128). Interestingly, diminishing myocardial autophagy in cardiomyocyte-specific Beclin-1+/- mice partially rescued myocardial function following pressure overload. Conversely, inducing autophagy in cardiomyocytes (via overexpression of Beclin-1) significantly increases mortality and cardiac remodeling following pressure overload (127), suggesting autophagy is maladaptive during cardiac stress. However, genetic disruption of myocardial autophagy via cardiomyocyte-specific deletion of autophagy related gene 5 (ATG5) exacerbated hypertrophy and remodeling during pressure overload (129). One possible explanation for these seemingly opposing observations is with regards to the manner in which autophagy is disrupted; if inhibited later in the process (as opposed to initiation), autophagosomes will accumulate within the myocardium, thus impairing cellular function. Consistent with this concept, doxorubicin-induced cardiomyopathy is characterized by an imbalance in autophagy initiation versus completion, resulting in autophagasome accumulation and cardiomyocyte dysfunction (130).

The UPS also plays a critical role in protein turnover. Accumulation of ubiquitinated proteins has been consistently observed across studies investigating human HF samples (124,126,131,132). This could result from an imbalance between the activity of ubiquitin ligases, de-ubiquitinating enzymes, and the proteasome. In the latter case, studies assessing proteasome activity have produced inconsistent results. For example, Birks et al reported increased 20S-proteasome chymotrypsin-like activity (132), while Day et al showed chymotrypsin-like and caspase-like proteasome activities were reduced (133). Interestingly, proteasome activity increases in patients after LVAD implantation (131). Additional studies are required to elucidate fully the contribution of perturbed UPS function in the etiology of HF.

Metabolic Dyssynchrony During Heart Failure – An Engine Flooded with Fuel?

Previous sections have outlined macronutrient metabolic perturbations during HF, the potential mechanisms leading to their occurrence, and their potential contribution toward contractile dysfunction of the heart. Here, we propose a unifying hypothesis for the metabolic origins of HF, based on the concept that the failing heart is oversupplied with macronutrients, leading to an imbalance in fuel availability and utilization, and subsequent accumulation of key metabolic intermediates that worsen contractile function of the heart (Figure 4). Rationale for this model will be discussed.

Figure 4Figure 4
Hypothetical Model for the Metabolic Origins of Heart Failure

During HF, the myocardium is undoubtedly in a state of dyssynchrony with regards to energy demand and ATP generation. Accordingly, compensatory mechanisms attempt to regain synchrony, through decreasing workload and increasing metabolism. For example, increased ANP/BNP secretion promotes natreurisis, thus reducing workload (134). Elevation of these cardiokines, as well as various cytokines (e.g., TNFα) and sympathetic tone, also serve to signal fuel mobilization during HF, enhancing adipocyte lipolysis (releasing FAs), hepatic gluconeogenesis (releasing glucose), and skeletal muscle proteolysis (releasing amino acids, including BCAAs) (105,135,136). These fuels not only become available to the heart (for ATP generation), but also to extra-cardiac tissues, including the liver; increased FA availability promotes ketogenesis, thereby elevating circulating ketone bodies in HF subjects (96-99). Collectively, the failing myocardium is in an environment rich in fuels (Figure 4A).

The myocardium has a high capacity/preference for ketone body utilization, which attenuates utilization of other substrates; elevated ketone body utilization concomitant with decreased total CoA in the failing myocardium (42), will limit mitochondrial free CoA for FAO, pyruvate oxidation, and BCAA metabolism. One strategy to liberate CoA for continued oxidative metabolism involves exchanging the CoA with carnitine, and subsequent generation of acetyl-carnitine (as observed during HF; (101,102,137)). However, diminished carnitine levels in the failing heart (138) will attenuate FAO capacity further. Impairment of FAO in the face of elevated circulating FAs would promote diversion of FA species into signaling/lipotoxic pathways. Elevated ketone body utilization would also limit the activity status of PDH; in the face of elevated glucose uptake, an uncoupling between glycolysis and glucose oxidation ensues. Similarly, impairment of the BCKD due to co-factor perturbations and/or PTM, coupled with increased circulating BCAAs, will lead to accumulation of BCKA and mitochondrial dysfunction. The latter amplifies metabolic dyssynchrony further, due to activation of mechanisms designed to promote cardiomyocyte substrate uptake in the face of energetic deficit (e.g., AMPK activation promoting GLUT1/4 and CD36 translocation for glucose and FA uptake, respectively). Importantly, during diabetes, dyssynchrony between fuel availability and utilization will be amplified further, due to greater levels of circulating FAs, ketone bodies, glucose, and BCAAs. In other words, the failing myocardium can be considered an engine flooded with fuel.

According to the model described above (Figure 4), strategies designed to regain synchrony between energetic demand, substrate availability, and substrate utilization would be beneficial during HF. Established and emerging HF therapeutics include β-blockers and valsartan/saculcitril. Both treatments focus primarily on reduction of workload, which in turn would help regain synchrony due to attenuation of energetic demand. In addition, β-blockers help regain synchrony further through inhibition of lipolysis, thus decreasing substrate supply (FAs, and likely ketone bodies). In contrast, through promotion of lipolysis, valsartan/saculcitril has the potential to negatively affect metabolic synchrony, augmenting substrate supply further. Although no pharmacological strategy has been taken to specifically attenuate ketogenesis in the setting of HF, some may influence this indirectly. For example, nicotinic acid, an anti-lipolytic agent, has been proposed to be beneficial during ischemic heart disease (139); attenuation of lipolysis would reduce FAs available for ketogenesis and lipotoxicity. Similarly, inhibition of hepatic FAO would attenuate ketogenesis; this may contribute to the benefit of FAO inhibitors, such as trimetazidine, in the setting of HF (140-142). However, some FAO inhibitors, such as etomoxir, appear to have detrimental effects due to hepatic toxicity (143). According to our model, limited availability of specific cofactors (e.g., carnitine and CoA) during HF would exacerbate metabolic dyssynchrony. Interestingly, several studies suggest that carnitine supplementation has benefits during HF (144); whether pantothenoate (precursor for CoA biosynthesis) supplementation has benefit during HF is currently unknown. Promotion of oxidation of individual substrates, such as pyruvate and BCKA, also appears to be beneficial in animal models (107); whether this translates to the clinical setting is currently unknown. However, caution should be taken to promote the use of a single substrate in the presence of excess FA availability, as this in turn could result in further inhibition of FAO, and potentially lipotoxicity.

Acknowledgments

Because of space constraints, the authors could not include all of the relevant citations on the subject matter, for which they apologize.

Funding: This work was supported by the National Institutes of Health (NIH) HL106199, HL074259, HL123574, and HL122974 to Dr. Young, HL111322 and HL133011 to Dr. Wende, and AHA 16POST270100009 to Dr. McGinnis.

Abbreviations

AA
amino acid
BCAA
branched-chain amino acids
EF
ejection fraction
FA
fatty acid
FAO
fatty acid oxidation
GCN2
general control nonderepressible 2
GLOX
glucose oxidation
HBP
hexosamine biosynthesis pathway
HF
heart failure
IR
insulin resistance
LV
left ventricular
MI
myocardial infarction
PTM
post-translational modification
ROS
reactive oxygen species
TauT
taurine transporter

Footnotes

Disclosures: All authors reported that they have no relationships with industry relevant to the contents of this paper to disclose.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Brown DI, Griendling KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res. 2015;116:531–49. [PMC free article] [PubMed]
2. Bers DM. Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu Rev Physiol. 2014;76:107–27. [PubMed]
3. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial Fatty Acid metabolism in health and disease. Physiol Rev. 2010;90:207–58. [PubMed]
4. Allard M, Schonekess B, Henning S, English D, Lopaschuk G. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994;267:H742–H750. [PubMed]
5. Goodwin G, Taylor C, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530–29539. [PubMed]
6. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest. 1987;79:359–66. [PMC free article] [PubMed]
7. Kato T, Niizuma S, Inuzuka Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circulation Heart failure. 2010;3:420–30. [PubMed]
8. Osorio JC, Stanley WC, Linke A, et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002;106:606–12. [PubMed]
9. Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271–7. [PubMed]
10. Yazaki Y, Isobe M, Takahashi W, et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart. 1999;81:153–9. [PMC free article] [PubMed]
11. Heather LC, Cole MA, Lygate CA, et al. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc Res. 2006;72:430–7. [PubMed]
12. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837–42. [PubMed]
13. Barger P, Kelly D. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238–245. [PubMed]
14. Lopaschuk G, Belke D, Gamble J, Itoi T, Schönekess B. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263–276. [PubMed]
15. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988;11:416–26. [PubMed]
16. Beer M, Seyfarth T, Sandstede J, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 2002;40:1267–74. [PubMed]
17. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012;59:802–8. [PMC free article] [PubMed]
18. Sharma S, Adrogue J, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692–1700. [PubMed]
19. Abdurrachim D, Luiken JJ, Nicolay K, Glatz JF, Prompers JJ, Nabben M. Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res. 2015;106:194–205. [PubMed]
20. Exil VJ, Roberts RL, Sims H, et al. Very-long-chain acyl-coenzyme a dehydrogenase deficiency in mice. Circ Res. 2003;93:448–55. [PubMed]
21. Xiong D, He H, James J, et al. Cardiac-specific VLCAD deficiency induces dilated cardiomyopathy and cold intolerance. Am J Physiol Heart Circ Physiol. 2014;306:H326–38. [PubMed]
22. Noh HL, Okajima K, Molkentin JD, Homma S, Goldberg IJ. Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab. 2006;291:E755–60. [PubMed]
23. Ellis JM, Mentock SM, Depetrillo MA, et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. Mol Cell Biol. 2011;31:1252–62. [PMC free article] [PubMed]
24. Kienesberger PC, Pulinilkunnil T, Nagendran J, et al. Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc Res. 2013;99:442–51. [PMC free article] [PubMed]
25. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JR. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation. 2004;109:1550–7. [PubMed]
26. Lehman JJ, Boudina S, Banke NH, et al. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol. 2008;295:H185–96. [PubMed]
27. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005;112:2339–46. [PubMed]
28. Kolwicz SC, Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111:728–38. [PMC free article] [PubMed]
29. Okere IC, Young ME, McElfresh TA, et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension. 2006;48:1116–23. [PubMed]
30. Berthiaume JM, Young ME, Chen X, McElfresh TA, Yu X, Chandler MP. Normalizing the metabolic phenotype after myocardial infarction: Impact of subchronic high fat feeding. J Mol Cell Cardiol. 2012;53:125–33. [PMC free article] [PubMed]
31. Okere IC, Chess DJ, McElfresh TA, et al. High-fat diet prevents cardiac hypertrophy and improves contractile function in the hypertensive dahl salt-sensitive rat. Clinical and experimental pharmacology & physiology. 2005;32:825–31. [PubMed]
32. Raher MJ, Thibault HB, Buys ES, et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol Heart Circ Physiol. 2008;295:H2495–502. [PubMed]
33. Stanley WC, Dabkowski ER, Ribeiro RF, Jr, O'Connell KA. Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res. 2012;110:764–76. [PMC free article] [PubMed]
34. Chiu HC, Kovacs A, Blanton RM, et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res. 2005;96:225–33. [PubMed]
35. Chiu HC, Kovacs A, Ford DA, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813–22. [PMC free article] [PubMed]
36. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol. 2009;54:1637–46. [PubMed]
37. He L, Kim T, Long Q, et al. Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation. 2012;126:1705–16. [PMC free article] [PubMed]
38. Tucci S, Flogel U, Hermann S, Sturm M, Schafers M, Spiekerkoetter U. Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD(-/-)) mice. Biochim Biophys Acta. 2014;1842:677–85. [PubMed]
39. Oka S, Zhai P, Yamamoto T, et al. Peroxisome Proliferator Activated Receptor-alpha Association With Silent Information Regulator 1 Suppresses Cardiac Fatty Acid Metabolism in the Failing Heart. Circulation Heart failure. 2015;8:1123–32. [PMC free article] [PubMed]
40. Alrob OA, Sankaralingam S, Ma C, et al. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res. 2014;103:485–97. [PMC free article] [PubMed]
41. Jing E, O'Neill BT, Rardin MJ, et al. Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes. 2013;62:3404–17. [PMC free article] [PubMed]
42. Reibel DK, Uboh CE, Kent RL. Altered coenzyme A and carnitine metabolism in pressure-overload hypertrophied hearts. Am J Physiol. 1983;244:H839–43. [PubMed]
43. Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol. 1990;65:755–60. [PubMed]
44. Lee CF, Tian R. Mitochondrion as a Target for Heart Failure Therapy- Role of Protein Lysine Acetylation. Circ J. 2015;79:1863–70. [PubMed]
45. Depré C, Vanoverschelde JLJ, Taegtmeyer H. Glucose for the Heart. Circulation. 1999;99:578–588. [PubMed]
46. Riehle C, Abel ED. Insulin Signaling and Heart Failure. Circ Res. 2016;118:1151–69. [PMC free article] [PubMed]
47. Harmancey R, Lam TN, Lubrano GM, Guthrie PH, Vela D, Taegtmeyer H. Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. FASEB J. 2012;26:3118–26. [PubMed]
48. Doenst T, Pytel G, Schrepper A, et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res. 2010;86:461–70. [PubMed]
49. Helfand BK, Maselli NJ, Lessard DM, et al. Elevated serum glucose levels and survival after acute heart failure: A population-based perspective. Diabetes and Vascular Disease Research. 2015;12:119–125. [PubMed]
50. Sud M, Wang X, Austin PC, et al. Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes. European Heart Journal. 2015;36:924–931. [PubMed]
51. Riehle C, Abel ED. Insulin Signaling and Heart Failure. Circulation research. 2016;118:1151–1169. [PMC free article] [PubMed]
52. Dei Cas A, Khan SS, Butler J, et al. Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC: Heart Failure. 2015;3:136–145. [PubMed]
53. Sung MM, Hamza SM, Dyck JRB. Myocardial Metabolism in Diabetic Cardiomyopathy: Potential Therapeutic Targets. Antioxidants & Redox Signaling. 2015;22:1606–1630. [PubMed]
54. Wende AR. Post-translational modifications of the cardiac proteome in diabetes and heart failure. Proteomics Clinical Applications. 2016;10:25–38. [PMC free article] [PubMed]
55. Shao D, Tian R. Glucose Transporters in Cardiac Metabolism and Hypertrophy. Compr Physiol. 2015;6:331–51. [PMC free article] [PubMed]
56. Kundu BK, Zhong M, Sen S, Davogustto G, Keller SR, Taegtmeyer H. Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: Review of a hypothesis. Cardiology. 2015;130:211–220. [PMC free article] [PubMed]
57. Azam MA, Wagg CS, Massé S, et al. Feeding the fibrillating heart: Dichloroacetate improves cardiac contractile dysfunction following VF. American Journal of Physiology - Heart and Circulatory Physiology. 2015;309:H1543–H1553. [PubMed]
58. Grossman AN, Opie LH, Beshansky JR, Ingwall JS, Rackley CE, Selker HP. Glucose-Insulin-Potassium Revived. Circulation. 2013;127:1040–1048. [PubMed]
59. Joost HG, Bell GI, Best JD, et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab. 2002;282:E974–6. [PubMed]
60. Aerni-Flessner L, Abi-Jaoude M, Koenig A, Payne M, Hruz PW. GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovascular diabetology. 2012;11:63. [PMC free article] [PubMed]
61. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic Gene Expression in Fetal and Failing Human Heart. Circulation. 2001;104:2923–2931. [PubMed]
62. Ciccarelli M, Chuprun JK, Rengo G, et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation. 2011;123:1953–62. [PMC free article] [PubMed]
63. Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol. 1970;218:153–9. [PubMed]
64. Liao R, Jain M, Cui L, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106:2125–31. [PubMed]
65. Pereira RO, Wende AR, Olsen C, et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. Journal of the American Heart Association. 2013;2:e000301. [PMC free article] [PubMed]
66. Pereira RO, Wende AR, Olsen C, et al. GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure. Journal of molecular and cellular cardiology. 2014;72:95–103. [PMC free article] [PubMed]
67. Tian R, Abel ED. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation. 2001;103:2961–2966. [PubMed]
68. DeBosch BJ, Chen Z, Finck BN, Chi M, Moley KH. Glucose Transporter-8 (GLUT8) Mediates Glucose Intolerance and Dyslipidemia in High-Fructose Diet-Fed Male Mice. Molecular Endocrinology. 2013;27:1887–1896. [PubMed]
69. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134:752–72. [PubMed]
70. Pham D, Albuquerque Rocha N, McGuire DK, Neeland IJ. Impact of empagliflozin in patients with diabetes and heart failure. Trends Cardiovasc Med. 2016 [PubMed]
71. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84:111–8. [PMC free article] [PubMed]
72. Kashiwagi Y, Nagoshi T, Yoshino T, et al. Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. PLoS One. 2015;10:e0130605. [PMC free article] [PubMed]
73. Son NH, Ananthakrishnan R, Yu S, et al. Cardiomyocyte Aldose Reductase Causes Heart Failure and Impairs Recovery from Ischemia. PLoS ONE. 2012;7:e46549. [PMC free article] [PubMed]
74. Vimercati C, Qanud K, Mitacchione G, et al. Beneficial effects of acute inhibition of the oxidative pentose phosphate pathway in the failing heart. Am J Physiol Heart Circ Physiol. 2014;306:H709–17. [PubMed]
75. Burke MA, Chang S, Wakimoto H, et al. Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight. 2016;1 [PMC free article] [PubMed]
76. Ussher JR, Jaswal JS, Lopaschuk GD. Pyridine nucleotide regulation of cardiac intermediary metabolism. Circulation research. 2012;111:628–41. [PubMed]
77. Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. American Journal of Physiology - Heart and Circulatory Physiology. 2013;304:H491–H500. [PubMed]
78. Hardivillé S, Hart GW. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. Cell metabolism. 2014;20:208–213. [PMC free article] [PubMed]
79. Lunde IG, Aronsen JM, Kvaløy H, et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiological Genomics. 2012;44:162–172. [PubMed]
80. Marsh SA, Collins HE, Chatham JC. Protein O-GlcNAcylation and cardiovascular (patho)physiology. Journal of Biological Chemistry. 2014;289:34449–34456. [PMC free article] [PubMed]
81. Dassanayaka S, Jones SP. O-GlcNAc and the cardiovascular system. Pharmacology & therapeutics. 2014;142:62–71. [PMC free article] [PubMed]
82. Erickson JR, Pereira L, Wang L, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502:372–6. [PMC free article] [PubMed]
83. Zhu-Mauldin X, Marsh SA, Zou L, Marchase RB, Chatham JC. Modification of STIM1 by O-linked N-acetylglucosamine (O-GlcNAc) attenuates store-operated calcium entry in neonatal cardiomyocytes. J Biol Chem. 2012;287:39094–106. [PMC free article] [PubMed]
84. Ramirez-Correa G, Ma J, Slawson C, et al. Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ sensitivity in diabetic cardiac muscle. Diabetes. 2015;64:3573–87. [PMC free article] [PubMed]
85. Ngoh GA, Watson LJ, Facundo HT, Jones SP. Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. Amino Acids. 2011;40:895–911. [PMC free article] [PubMed]
86. Kimura I, Inoue D, Maeda T, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41) Proc Natl Acad Sci U S A. 2011;108:8030–5. [PubMed]
87. Valayannopoulos V, Bajolle F, Arnoux JB, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011;70:638–41. [PubMed]
88. Al-Zaid NS, Dashti HM, Mathew TC, Juggi JS. Low carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia. Acta Cardiol. 2007;62:381–9. [PubMed]
89. Liu J, Wang P, Zou L, et al. High-fat, low-carbohydrate diet promotes arrhythmic death and increases myocardial ischemia-reperfusion injury in rats. Am J Physiol Heart Circ Physiol. 2014;307:H598–608. [PubMed]
90. Wang P, Tate JM, Lloyd SG. Low carbohydrate diet decreases myocardial insulin signaling and increases susceptibility to myocardial ischemia. Life Sci. 2008;83:836–44. [PMC free article] [PubMed]
91. Schugar RC, Moll AR, Andre d'Avignon D, Weinheimer CJ, Kovacs A, Crawford PA. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Molecular metabolism. 2014;3:754–69. [PMC free article] [PubMed]
92. Stowe KA, Burgess SC, Merritt M, Sherry AD, Malloy CR. Storage and oxidation of long-chain fatty acids in the C57/BL6 mouse heart as measured by NMR spectroscopy. FEBS Lett. 2006;580:4282–7. [PubMed]
93. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. American Journal of Physiology Heart and Circulatory Physiology. 2013;304:H1060–H1076. [PubMed]
94. Janardhan A, Chen J, Crawford PA. Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J. 2011;38:533–8. [PMC free article] [PubMed]
95. Lommi J, Koskinen P, Naveri H, Harkonen M, Kupari M. Heart failure ketosis. J Intern Med. 1997;242:231–8. [PubMed]
96. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992;340:88–92. [PubMed]
97. Kupari M, Lommi J, Ventila M, Karjalainen U. Breath acetone in congestive heart failure. Am J Cardiol. 1995;76:1076–8. [PubMed]
98. Marcondes-Braga FG, Gutz IG, Batista GL, et al. Exhaled acetone as a new biomaker of heart failure severity. Chest. 2012;142:457–66. [PubMed]
99. Yokokawa T, Sugano Y, Shimouchi A, et al. Exhaled Acetone Concentration Is Related to Hemodynamic Severity in Patients With Non-Ischemic Chronic Heart Failure. Circ J. 2016;80:1178–86. [PubMed]
100. Zordoky BN, Sung MM, Ezekowitz J, et al. Metabolomic fingerprint of heart failure with preserved ejection fraction. PLoS One. 2015;10:e0124844. [PMC free article] [PubMed]
101. Aubert G, Martin OJ, Horton JL, et al. The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation. 2016;133:698–705. [PMC free article] [PubMed]
102. Bedi KC, Jr, Snyder NW, Brandimarto J, et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016;133:706–16. [PMC free article] [PubMed]
103. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211–4. [PMC free article] [PubMed]
104. Hakuno D, Hamba Y, Toya T, Adachi T. Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure. PLoS One. 2015;10:e0117325. [PMC free article] [PubMed]
105. Pasini E, Aquilani R, Dioguardi FS, D'Antona G, Gheorghiade M, Taegtmeyer H. Hypercatabolic syndrome: molecular basis and effects of nutritional supplements with amino acids. Am J Cardiol. 2008;101:11E–15E. [PubMed]
106. Lai L, Leone TC, Keller MP, et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circulation Heart failure. 2014;7:1022–31. [PMC free article] [PubMed]
107. Sun H, Olson KC, Gao C, et al. Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation. 2016;133:2038–49. [PMC free article] [PubMed]
108. Ito T, Kimura Y, Uozumi Y, et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol. 2008;44:927–37. [PubMed]
109. Schaffer SW, Shimada-Takaura K, Jong CJ, Ito T, Takahashi K. Impaired energy metabolism of the taurinedeficient heart. Amino acids. 2016;48:549–58. [PubMed]
110. Jong CJ, Azuma J, Schaffer S. Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino acids. 2012;42:2223–32. [PubMed]
111. Ramila KC, Jong CJ, Pastukh V, Ito T, Azuma J, Schaffer SW. Role of protein phosphorylation in excitation-contraction coupling in taurine deficient hearts. Am J Physiol Heart Circ Physiol. 2015;308:H232–9. [PubMed]
112. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56:95–9. [PubMed]
113. Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57:333–7. [PubMed]
114. Carubelli V, Castrini AI, Lazzarini V, Gheorghiade M, Metra M, Lombardi C. Amino acids and derivatives, a new treatment of chronic heart failure? Heart failure reviews. 2015;20:39–51. [PubMed]
115. Aquilani R, Viglio S, Iadarola P, et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol. 2008;101:104E–110E. [PubMed]
116. Lombardi C, Carubelli V, Lazzarini V, et al. Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. Clinical Medicine Insights Cardiology. 2014;8:39–44. [PMC free article] [PubMed]
117. Tanada Y, Shioi T, Kato T, Kawamoto A, Okuda J, Kimura T. Branched-chain amino acids ameliorate heart failure with cardiac cachexia in rats. Life Sci. 2015;137:20–7. [PubMed]
118. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3. [PubMed]
119. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. The Journal of clinical investigation. 2005;115:2108–18. [PMC free article] [PubMed]
120. Riehle C, Wende AR, Sena S, et al. Insulin receptor substrate signaling suppresses neonatal autophagy in the heart. The Journal of clinical investigation. 2013;123:5319–33. [PMC free article] [PubMed]
121. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050–5. [PubMed]
122. Shende P, Plaisance I, Morandi C, et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011;123:1073–82. [PubMed]
123. Lu Z, Xu X, Fassett J, et al. Loss of the eukaryotic initiation factor 2alpha kinase general control nonderepressible 2 protects mice from pressure overload-induced congestive heart failure without affecting ventricular hypertrophy. Hypertension. 2014;63:128–35. [PMC free article] [PubMed]
124. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003;107:984–91. [PubMed]
125. Knaapen MW, Davies MJ, De Bie M, Haven AJ, Martinet W, Kockx MM. Apoptotic versus autophagic cell death in heart failure. Cardiovascular research. 2001;51:304–12. [PubMed]
126. Kassiotis C, Ballal K, Wellnitz K, et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation. 2009;120:S191–7. [PMC free article] [PubMed]
127. Zhu H, Tannous P, Johnstone JL, et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. The Journal of clinical investigation. 2007;117:1782–93. [PubMed]
128. Shirakabe A, Zhai P, Ikeda Y, et al. Drp1-Dependent Mitochondrial Autophagy Plays a Protective Role Against Pressure Overload-Induced Mitochondrial Dysfunction and Heart Failure. Circulation. 2016;133:1249–63. [PMC free article] [PubMed]
129. Nakai A, Yamaguchi O, Takeda T, et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nature medicine. 2007;13:619–24. [PubMed]
130. Li DL, Wang ZV, Ding G, et al. Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification. Circulation. 2016;133:1668–87. [PMC free article] [PubMed]
131. Predmore JM, Wang P, Davis F, et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation. 2010;121:997–1004. [PMC free article] [PubMed]
132. Birks EJ, Latif N, Enesa K, et al. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovascular research. 2008;79:472–80. [PubMed]
133. Day SM, Divald A, Wang P, et al. Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure. Circulation Heart failure. 2013;6:544–9. [PMC free article] [PubMed]
134. Ghosh N, Haddad H. Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value. Canadian journal of physiology and pharmacology. 2011;89:587–91. [PubMed]
135. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008;19:130–7. [PubMed]
136. Tenenbaum A, Fisman EZ. Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2004;4:269–80. [PubMed]
137. Rame JE. Metabolic Staging in Human Heart Failure: Circulating Acylcarnitines and the Failing Heart's Energetic Signature. J Am Coll Cardiol. 2016;67:300–2. [PubMed]
138. Atar D, Spiess M, Mandinova A, Cierpka H, Noll G, Luscher TF. Carnitine--from cellular mechanisms to potential clinical applications in heart disease. European journal of clinical investigation. 1997;27:973–6. [PubMed]
139. Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep. 2005;7:63–70. [PubMed]
140. Lopatin YM, Rosano GM, Fragasso G, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International journal of cardiology. 2016;203:909–15. [PubMed]
141. Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59:913–22. [PubMed]
142. Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011;97:1495–500. [PubMed]
143. Holubarsch CJ, Rohrbach M, Karrasch M, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clinical science. 2007;113:205–12. [PubMed]
144. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci. 2004;1033:79–91. [PubMed]